Savings in medicines reimbursements and other Health Insurance Act amendments
The savings measures in force as of the beginning of the year 2016 will cut the medicines reimbursement expenditure of Kela, the National Insurance Institution, by about 80 million euro. These savings are part of the Finnish austerity measures. The savings are targeted both at medicine users and at the pharmaceutical branch actors.
Reform of the administration and funding of social affairs and health care in Finland
For years, a major reform of the social welfare and healthcare systems has been in preparation in Finland. The reform aims at equality of the population, integration of the care and significant cost savings. The reform is necessary because the majority of the municipalities – the administrative level that shoulders the responsibility for social welfare and healthcare expenses – are too small to cope with the increased expenses brought about by the ageing of the population.
Self-care being extended
New self-care possibilities have reached patients as two significant OTC switches have been made in Finland recently. At the end of 2015 the painkiller naproxen (250 mg 10 tablet pack) and migraine treatment sumatriptan (50mg 2 tablet pack) have been granted an OTC license by the national medicines authority Fimea.
Team Finland Health spreads the word: Finland is a good place for medicines research
Team Finland Health is a joint public sector program that facilitates the internationalization and exporting efforts of Finnish health care companies. Team Finland Health implements the Growth Strategy of research and innovation actions of the Health Sector. The strategy is also engaged in developing the research ecosystem in Finland.
New broader interpretation on defining the non-interventional trials
The EU clinical trial regulation 536/2014 will harmonise the interpretation of interventional vs non-interventional trials (NIS) in EU but meanwhile Finnish Medicines Agency Fimea has decided to make three changes to the current interpretation to allow more non-interventional trials in Finland on well-defined grounds.